See the original post:
Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh